Aims/hypothesis. Oxidized LDL is immunogenic and immune complexes formed by oxidized LDL and corresponding antibodies are pro-atherogenic and pro-inflammatory. Considering that macroalbuminuria is a risk factor for coronary heart disease and that common pathogenic factors for atherosclerosis and glomerulosclerosis exist, our aim was to determine whether the amount and/or characteristics of oxidized LDL-antioxidized LDL complexes correlated with the degree of albuminuria in patients with Type I (insulin-dependent) diabetes mellitus. Methods. We studied 33 macroalbuminuric patients (albumin excretion rate >300 mg/24 h) and 29 microalbuminuric patients (albumin excretion rate ≥30 mg/ 24 h and ≤300 mg/24 h) who were matched for age, sex and HbA 1C concentrations with 43 patients with normal albuminuria. In all patients we isolated and characterized oxidized LDL-anti-oxidized LDL complexes. A subgroup of 47 patients (22 with normal albuminuria, 11 with microalbuminuria, and 14 with macroalbuminuria) was randomly selected from the larger group for characterization of the antibody moiety of oxidized LDL immune complexes.
Patients with Type I (insulin-dependent) diabetes mellitus are at an increased risk of developing microvascular and macrovascular disease [1, 2, 3] , macrovascular disease being the main cause of morbidity and mortality in these patients. Nephropathy, a microvascular complication of diabetes, has been shown to be an important risk factor for macrovascular disease [4, 5] , suggesting that the two processes are interrelated. Several hypotheses have been put forward to explain how nephropathy accelerates the development of macrovascular disease. The most commonly accepted hypothesis postulates that abnormalities in lipoprotein metabolism secondary to nephropathy lead to the formation of atherogenic lipoproteins and, as a consequence, to the accelerated development of atherosclerosis [6, 7] . Some of the better characterized lipoprotein changes in diabetic nephropathy include LDL glycation and oxidation as well as the formation of advanced glycated end products (AGE)-LDL [8] . These modified lipoproteins greatly contribute not only to the development of atherosclerosis but also to further progression of diabetic nephropathy [9, 10] . OxLDL has been found in both atherosclerotic plaques and in glomerulosclerotic lesions. It is believed to act as a chemoattractant, recruiting macrophages into atheromatous as well as into glomerulosclerotic lesions [9, 11, 12] . Besides inducing accumulation of foam cells in both atherosclerotic and glomerulosclerotic lesions, oxLDL induces cell proliferation (smooth muscle cells in atherosclerotic lesions and mesangial cells in glomerulosclerosis) and causes expansion of extracellular matrix in both processes [9, 13] .
One other property of oxLDL that has attracted considerable attention is its immunogenicity, as reflected by the formation of oxLDL autoantibodies [11, 14, 15] . Evidence for the involvement of autoantibodies against modified forms of LDL in atherogenesis has been supported by data from experimental models and clinical studies [11, 16] , but other studies examining the correlation between the concentrations of antibodies to oxLDL and markers of atherosclerosis have yielded contradictory and inconclusive results [14, 17, 18] . It has been shown, however, that in humans oxLDLcontaining immune complexes (oxLDL-IC) are present in the blood of subjects with and without demonstrable vascular disease and seem to contribute to atherosclerosis via enhanced intracellular cholesteryl ester accumulation in macrophages [19, 20, 21, 22] . Studies done in our laboratory [16, 23] have shown that the most efficient mechanism for the transformation of human monocyte-derived macrophages into foam cells is their incubation with LDL-IC prepared with human LDL and rabbit anti-LDL antibodies. Similar observations have also been reported using immune complexes isolated from human serum [20] . Finally, the presence of high LDL-IC levels and low levels of free oxLDL antibodies precedes and predict the development of coronary heart disease in Type I diabetes [14, 24] .
Considering the wealth of data supporting a pathogenic role of oxidized LDL-IC in atherosclerosis, we decided to test the hypothesis that nephropathy is associated with an increased concentration of circulating oxLDL-IC. We determined the concentration and avidity of circulating antibodies to oxLDL, as well as the concentration and avidity of antibodies purified from circulating immune complexes, in patients with Type I diabetes, subdivided into groups according to their degree of albuminuria.
Subjects and methods
Subjects and samples. Samples for this study were chosen from fasting blood samples collected from 1068 patients with Type I diabetes enrolled in the Epidemiology of Diabetes Intervention and Complications (EDIC) study between May 1997 and May 2000. Blood was collected by venipuncture at the EDIC clinics, clotted at room temperature for 1 h and centrifuged to separate serum. EDTA (1 mg/ml) was added to the serum to prevent LDL oxidation, serum aliquots were immediately stored at -70°C, and they were shipped monthly to the Medical University of South Carolina on dry ice. Informed consent as approved by the Institutional Review Board for Human Research of every Center involved in the DCCT/EDIC trial was obtained from each subject included in this study. The Institutional Review Board for Human Research of the Medical University of South Carolina approved our experimental protocol.
The Biostatistical Core of our Molecular Risk Factors Program Project selected sera from 105 out of 1068 patients for this study. The patients were selected based on their AER, according to the average albuminuria measured in two urine specimens collected within a 2 year period, one before and the other after the collection of the blood samples in which all the measurements were reported. According to the EDIC protocol fasting blood samples and renal assessment studies were done in alternate years in every patient. Following the American Diabetes Association criteria [25] , patients excreting less than 30 mg/24 h of albumin in the urine were considered normoalbuminuric; those excreting 30 to 300 mg/24 h were classified as microalbuminuric, and those excreting more than 300 mg/24 h were considered macroalbuminuric. Patients with abnormal albuminuria were matched to patients with normal albuminuria for sex, age (within 4 years), and HbA 1c concentrations (within 1% except for three cases where the HbA 1c was greater than 9.5% and the differences exceeded 1%). Duration of diabetes was maintained as close as possible between groups. The selected group included 33 patients with macroalbuminuria and 29 with microalbuminuria, matched with 43 patients with normal albuminuria (Table 1) .
A subgroup of 47 patients was selected from the larger group of 105 patients for detailed characterization of soluble immune complexes. The selection criteria included availability of sufficient sera to do isolation studies and matching with a normoalbuminuric patient. We selected two groups of patients, one normoalbuminuric and the other with abnormal albuminuria. The final distribution of the 47 sera was as follows: 22 from patients with normal albuminuria, 11 from patients with microalbuminuria, and 14 from patients with macroalbuminuria.
Assay of oxLDL antibodies. Antibodies to oxLDL were measured by the competitive enzyme immunoassay described previously [17] . The assays were calibrated with a series of dilutions of a human serum calibrator with known concentrations of oxLDL antibody [26] . The antibody concentrations were calculated from the difference in O.D. (414 nm) between unabsorbed and absorbed aliquots of the tested sera and were expressed in µg/ml.
Isolation of circulating oxLDL antibodies. OxLDL antibodies were isolated using an affinity chromatography protocol that uses Sepharose-linked oxLDL as substrate [27, 28] . To isolate anti-oxLDL antibodies from serum samples, 2 ml of serum were diluted in 8 ml of 0.01 mol/l NaHCO 3 buffer, pH 8.3 and allowed to diffuse into the oxLDL-Sepharose column. After loading, the column was incubated overnight at 4°C, and unbound proteins were washed off with the equilibrating buffer. The bound antibodies were eluted with 0.1 mol/l NaHCO 3 (pH 8.3) buffer containing 0.5 mol/l NaCl. The purified antibodies were stored at -20°C until analysed.
Characterization of soluble immune complexes (IC) precipitated with polyethylene glycol (PEG).
A modification of the technique described previously [29] was used to precipitate immune complexes from sera. In brief, a 3 ml aliquot of serum was gently mixed under constant and gentle stirring with an equal volume of a freshly prepared and sterilized 7% polyethylene glycol (PEG) solution in borate buffered saline (BBS), pH 8.4. The samples, containing a final PEG concentration of 3.5%, were incubated overnight at 4°C and then centrifuged at 3000 rpm for 20 min. The precipitates were washed once with 14 ml of chilled 3.5% PEG in BBS, centrifuged again and gently resuspended at 37°C in 3 ml of PBS containing 0.01% EDTA, pH 7.4. Most studies were carried out with freshly isolated IC. When necessary, aliquots were stored at -20°C until further testing.
The protein content of PEG-precipitated immune complexes was measured by a modified Lowry assay [23] . The cholesterol content of the precipitated IC was analysed by gas chromatography [30] after extraction of the PEG-precipitated immune complexes with a mixture of chloroform:methanol (2:1, v/v) [14] . The apolipoprotein B content of IC was measured by quantitative immunoelectrophoresis [31] .
Isolation of IgG from PEG-precipitated immune complexes.
Aliquots of purified IC stored at -20°C were thawed and warmed to 37°C for 20 min and resuspended by gentle vortexing. The resuspended IC samples were loaded onto a protein G column (Pharmacia) and the column was washed with 0.1 mol/l NaHCO 3 +0.5 mol/l NaCl buffer, pH 8.3. The ionic strength of this buffer is the same as used to elute oxLDL antibodies from an immobilized oxLDL column [27, 28] and should therefore dissociate any oxLDL-IgG containing IC, allowing the elution of oxLDL while retaining IgG due to the high avidity interaction between IgG and protein G. After washing, IgG was eluted using 0.1 mol/l Glycine-HCl buffer, pH 2.7, and the fractions were immediately neutralized with 1 mol/l Tris-HCl buffer, pH 9.0. Neutralized eluates were then dialysed against PBS overnight, aliquoted, and stored at -20°C until tested.
Determination of the dissociation constants (Kd) of purified
antibodies. An estimate of the avidity of each purified antibody eluate was obtained through the measurement of Kd by competitive enzyme immunoassay, using a modification of a previously described method [32] , as adapted to the characterization of oxLDL antibodies [27] . For this purpose, we coated flat-bottomed Immulon type I plates with 7.5 µg of oxLDL per well. Purified oxLDL antibody was used at a final concentration of 200 µg/ml. A series of antibody aliquots was absorbed using concentrations of oxLDL ranging from 7.36×10 -7 to 1.15×10 -8 mol. Absorbed and unabsorbed samples were incubated in oxLDL-coated plates overnight at 4°C, and after this step the samples were processed as described for the oxLDL antibody assay. The concentrations of antigen along with the absorbance values measured in unabsorbed and absorbed samples were used to construct a Scatchard plot of v/a versus v where v corresponds to bound antigen and v/a to bound antigen/free antigen concentration [32] . The slope of the plot was used to calculate the K d for each sample tested.
Statistical analysis.
Results are expressed as means ± standard error, unless stated differently. All data were analysed using InStat (GraphPad, San Diego, Calif., USA) and SAS (SAS Institute, version 8, Cary, N.C., USA) software. ANOVA, with Bonferroni correction, was used to compare the results of different tests in the three AER groups, using the data from patients with normal albuminuria as the control. A paired Student's t test between two measurements of oxidized LDL antibody concentrations in serum against concentrations of the same antibodies isolated from immune complexes was conducted. Analysis of covariance (ANOCOVA, Dunnett-Hsu correction) with normal albuminuria as control while adjusting for sex, age, HbA 1c among three AER groups was carried out as indicated. Additional details about statistical analysis can be found in the footnotes of Table 1 and on the legends of Figures 1 and 2 . A p value of less than 0.05 was considered significant.
Results
Clinical and laboratory characteristics of the subjects included in this study. The clinical and laboratory characteristics of the three subgroups studied are sum- Data are means ± SD. Statistical significance was determined by an ANOVA among three matched groups compared with normal albuminuria as a control group, testing within-group differences marized in Table 1 . The three subgroups were closely matched for sex, age, and degree of glycaemic control. Differences in their lipid profile were observed, as expected. When compared to the subjects with normoalbuminuria, the subjects with macroalbuminuria had increased concentrations of total cholesterol and triglycerides that reached statistical significance, while the patients with microalbuminuria had lower levels of HDL-cholesterol than those with macroalbuminuria or normoalbuminuria ( Table 1) .
Concentrations of circulating oxLDL antibodies.
The concentrations of circulating oxLDL antibodies in the three subgroups studied were increased in the groups with micro (54±9 mg/l) and macroalbuminuria (72±13 mg/l) relative to the normoalbuminuric group (44±5 mg/l). The increase did not reach statistical significance (p=0.0885). However, trend analysis comparing AER with concentrations of circulating oxLDL antibodies barely failed to achieve statistical significance (p=0.0520).
Correlation between the concentrations of cholesterol, Apo B, and oxLDL antibodies in PEG-precipitated IC and albumin excretion rates. Measurement of cholesterol, apolipoprotein B and ox LDL antibodies was done in immune complexes isolated by precipitation with 3.5% of PEG. The mean total cholesterol concentration in PEG-precipitated IC was higher in the macroalbuminuric (272±20 mg/l or 0.703±0.0517 mmol/l) and microalbuminuric (244±20 mg/l or 0.63±0.0517 mmol/l) groups, compared to the normoalbuminuric group (204±18 mg/l or 0.528±0.0465 mmol/l) (Fig. 1A) . The difference between the cholesterol content of IC in normoalbuminuric and macroalbuminuric groups reached statistical significance (p<0.03). Additionally, concentrations of apolipoprotein B in PEG-precipitated IC showed similar increases in the macroalbuminuric (134±10 mg/l) and microalbuminuric (110±11 mg/l) groups compared to the normoalbuminuric group (99±9 mg/l), with the difference reaching statistical significance when the macroalbuminuric and normoalbuminuric groups were compared (p<0.03, Fig. 1B) . In contrast to the concentrations of ApoB and cholesterol, there was no significant difference between the groups in the concentrations of oxLDL antibodies measured in the PEG precipitates.
Isolation of oxLDL antibodies from PEG-precipitated immune complexes.
IgG oxLDL antibodies from PEGprecipitated IC were isolated by affinity chromatography using immobilized protein G. Two different elution protocols were compared, and both yielded equivalent amounts of oxLDL antibody ( Table 2 ). The recovery of oxLDL antibody was approximately twofold higher than the amount loaded onto the column (60 µg loaded vs 127 or 131 µg recovered according to the Results are given in mg/l and data is expressed as means ± SEM. Statistical significance was determined by an analysis of covariance (ANOCOVA) with normal albuminuria as the control group and adjusted for sex, age, and HbA 1c . A significant difference (p<0.03) was observed between the contents of cholesterol and apolipoprotein B in PEG-precipitated IC between the group of patients with macroalbuminuria and the group of patients with normoalbuminuria Table 2 ), probably due to the interference of soluble IC in the antibody assay. We also found that the concentrations of oxLDL antibodies measured in the IgG fractions isolated from PEG-precipitated IC were higher than those measured in the sera from which the IC were isolated (Fig. 2) . We detected small amounts of oxLDL antibodies in protein G washout fractions (Table 2) , most probably corresponding to dissociated immune complexes containing immunoglobulin isotypes not bound by protein G.
Dissociation constants of free and IC-associated oxLDL antibodies.
We compared, in 47 of the 105 patients studied, the avidity of oxLDL antibodies isolated from serum with the avidity of oxLDL antibodies isolated from IC in the same patient. To avoid the probable interference of complexed antibodies with the accurate determination of dissociation constants we established an elution protocol that completely dissociated the IC. The eluate using the new protocol was virtually devoid of cholesterol (Table 2) . With this protocol we eluted oxLDL antibodies from the IC of the 47 patients studied and measured their Kd as described in methods. The Kd values of oxLDL antibodies isolated from the sera of patients in each of the three patient subgroups were virtually undistinguishable (Table 3) . In contrast, a comparison of Kd values from the serum antibodies and antibodies present in immune complexes in the same subject showed the later to be of higher avidity (serum antibody Kd=1.53±0.13 07×10 -8 mol/l; immune complex antibody Kd=0.98±0.06×10 -8 mol/l mol/l; p<0.001). Also, the average avidity of IgG antibodies isolated from PEG-precipitated IC from patients with AER equal or greater than 30 mg/24 h (microalbuminuric and macroalbuminuric) was higher (Kd=0.86 ±0.1× 10 -8 mol/l) than the average avidity of IgG antibodies isolated from PEG-precipitated IC from normoalbuminuric patients with AER below 30 mg/24 h (Kd=1,13 ±0.1×10 -8 mol/l). The differences between the Kd values measured in the three different groups did not reach statistical significance (Table 3 ) probably due to the small number of subjects in each subgroup, but a difference (p<0.05) was observed when the Kd values of the patients with normoalbuminuria were compared with those from all patients with abnormal albuminuria.
Discussion
Apart from the prevalence of nephropathy in Type I diabetes and its associated morbidity and mortality, the pathogenic mechanisms responsible for its development are still poorly understood. The development of nephropathy in Type I diabetes has been postulated to mimic, from a pathogenic point of view, the devel- . The volume of the isolated IgG samples was adjusted to be identical to the volume of serum that was originally precipitated, so that the antibody concentrations are directly comparable to those in unfractionated serum. The data in the graph is expressed as mean ± SEM. A significant difference (p<0.05) was found between the antibody levels in serum and in the IgG fraction separated from PEG-precipitated immune complexes using a two-tailed Student's t test for paired samples opment of systemic atherosclerosis [33] . The association between nephropathy progression and hypercholesterolemia [33] and animal studies that strongly suggest that hyperlipidaemia can contribute to the deterioration of renal function [34] support this postulation. The pathogenic mechanism proposed to explain how hyperlipidemia leads to glomerulosclerosis involves the infiltration of LDL, due to increased capillary permeability, into the glomerular mesangium followed by LDL oxidation by mesangial cells. As a consequence, recruitment and activation of inflammatory cells would take place, leading to the release of cytokines followed by proliferation of mesangial cells and expansion of the extracellular matrix [35] . This sequence of events would, in time, result in glomerulosclerosis [9, 13] . The pathogenic role of modified lipoproteins in atherosclerosis is well established. It has been investigated from two different angles: the direct pro-atherogenic effect of oxLDL [9, 10] and the consequences of the immune response directed against neoepitopes resulting from lipoprotein modification [11, 14, 15] . Support for the atherogenic role of oxLDL antibodies was initially found in some studies showing a positive correlation between increased circulating oxLDL antibody concentrations and atherosclerotic vascular disease [36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46] . Many other studies however failed to show such a correlation [17, 47, 48, 49, 50, 51, 52] . We and others have shown lower serum concentrations of antibodies to oxLDL but higher concentrations of immune complexes in subjects with diabetes-related complications [14, 24, 53] .
Some authors have questioned the pathogenic role of oxLDL antibodies based on the negative studies mentioned above and on results obtained with animal models [18] . Immunization of LDL receptor deficient rabbits with homologous MDA-LDL had an apparently protective effect relative to atherogenesis [54] . Similar observations were reported in ApoE deficient mice immunized with MDA-LDL [55] . However it was later shown that immunization of LDL receptor deficient rabbits with native LDL, although not inducing the formation of antibodies, had also a protective effect suggesting that such effect is not related to the production of oxLDL antibody [56] . More recently, it was reported that a human-derived oxLDL monoclonal antibody inhibited the uptake of oxLDL by macrophages [57] leading the authors to postulate that the humoral response to oxLDL in humans is protective. The monoclonal antibody in question, however, was produced as Fab fragments. Consequently, the antigen-antibody complexes could not interact with Fcγ receptors [58] , and this explains the lack of uptake by macrophages and the lack of pro-inflammatory and pro-atherogenic properties.
The pathogenic potential of oxLDL antibodies is best assessed by measuring LDL-containing IC as shown by several in vitro experiments. LDL-IC interact with the high avidity Fcγ receptor (FcγRI) of monocytes and macrophages [59] . This interaction results in cell activation, release of pro-inflammatory cytokines, metalloproteinases and reactive oxygen species, cholesterol ester accumulation, and unregulated expression of LDL receptors [19, 23, 60, 61, 62] . It was also shown that cholesterol-rich PEG-precipitated immune complexes had atherogenic properties when incubated with human macrophages [22] and this observation led to the proposal that LDL-IC could be used as markers of atherosclerosis [63] . Data from a prospective study in a group of Type I diabetic patients clearly shows that LDL-IC are a risk factor for the development of coronary heart disease in these patients [14, 24] .
When the possible correlation between oxLDL antibodies and diabetic nephropathy was first investigated no association was found between serum concentrations of oxLDL antibodies and diabetic nephropathy or nephropathy-related macroangiopathy [64] . In our study we were also unable to show a statistically significant correlation between circulating oxLDL antibody concentrations and proteinuria, although trend analysis showed a near significant correlation. Nevertheless, when we focused our attention on LDL-IC concentrations we found an association between LDL-IC and abnormal albuminuria. Higher concentrations of cholesterol and apolipoprotein B were detected in the immune complexes of subjects with abnormal AER, particularly those with macroalbuminuria. We were able to purify antigen-free IgG from PEG-precipitated immune complexes and show that it contained oxLDL antibodies, and that these antibodies were of higher avidity than free, circulating oxLDL antibodies. Furthermore, we have shown that the average avidity of antibodies contained in PEGprecipitated IC was higher in subjects with abnormal AER values than in subjects with normal AER. The nature of the LDL molecules found in the PEG-precipitated immune complexes could not be established directly by the assays of cholesterol and ApoB concentrations. However, the observation of oxLDL antibodies in the PEG-precipitated immune complexes strongly supports the hypothesis that the PEG-precipitable IC contain oxLDL and their corresponding antibodies.
Our report supports a pathogenic role for oxLDLcontaining IC in diabetic nephropathy. Our data suggests that the pathogenic potential of oxLDL IC is directly related to oxLDL antibody avidity. The correlation between antibody pathogenicity and avidity for antigen agrees with classical observations published by Winfield et al., who demonstrated in the late 1970s that the avidity of DNA antibodies eluted from deposited IC in patients with systemic lupus erythematosus was higher than the avidity of circulating antibodies of the same specificity [65] .
The formation of IC containing IgG oxLDL antibodies of higher avidity in patients with microalbuminuria and macroalbuminuria is likely to reflect the formation of stable complexes, able to activate pro-inflammatory mechanisms [66] . The pro-inflammatory potential of oxLDL IC is supported by our results showing that oxLDL antibodies are predominantly of the IgG1 and IgG3 isotypes [28] , known to activate the classic pathway of the complement system and to engage all known types of Fcγ receptors [67] .
The process by which oxLDL-IC can cause increased albuminuria is not clear. OxLDL has been shown to induce proliferation of mesangial cells, a prominent feature of diabetic nephropathy [68] , and cause the expansion of the extracellular matrix [9, 13] . In turn, mesangial cells have been shown to oxidize LDL in vitro [69] . This observation has obvious implications, because in situ oxidation of LDL would create the necessary conditions for the formation of LDL-IC in the mesangium. In the case of human macrophages, the higher atherogenic potential of ox-LDL IC relative to free oxLDL seems to be related to the engagement of FcγRI by the IC [59] . Human mesangial cells have been reported to express this same receptor after activation by interferon-γ [70] . It is not known if the uptake of oxLDL IC through this receptor can activate mesangial cells to the same extent as macrophages. If it does, the question of the in vivo cellular source of interferon-γ will arise. As in the pathogenesis of large vessel atherosclerosis, it is likely that a variety of immune cells are involved in the process. Activated T cells reacting with oxLDL and hsp-60-derived epitopes have been detected in atheromatous lesions [71] . A similar involvement at the glomerular level could account for the release of interferon-γ and mesangial-cell activation.
